Switzerland’s Nouscom bags €120 million to bring innovative cancer immunotherapy closer to clinical trials
Basel-based biotech Nouscom closed an oversubscribed €120 million Series D financing co-led by M Ventures and Revelation Partners to advance its neoantigen-based cancer immunotherapy. This is a sizeable late-stage biotech round relevant for deep-tech founders and investors tracking European clinical-stage financings.